Skip to main content
S&P 5007,580.07-1.82%DOW51,770.31-1.09%NASDAQ25,437.00-2.86%BTC$77,415.00+0.36%ETH$2,246.32+1.22%GOLD$3,884.90-3.63%OIL$102.95+0.93%
Smart Investors Daily
SID Premium
PE

NYSE · PEN

Penumbra, Inc.

Healthcare · Medical - Devices

$318.95

Down-$3.02 (-0.94%)

Updated Oct 31, 2026, 4:26 PM

SID Score

5.2/10

Composite research score

Smart Money

54/100

Neutral

Market cap
12.2B
P/E ratio
74.22
Dividend yield
0.00%
52-week range
$221.26 – $362.41
Volume
497.75K
Avg. volume
443.1K

Price performance · PEN

PEN price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 30, 2026

PEN closed at $318.95 after 21 trading sessions, up 0.44% for the selected period.

Last close
$318.95
Period change
+0.44%
Period low
$316.35
Period high
$325.22
Daily close
View OHLC price history
PEN OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 30, 2026$320.56$321.83$318.32$318.95497.75K
Oct 29, 2026$318.86$321.97$318.86$321.97672.77K
Oct 28, 2026$321.04$321.155$316.35$318.31851.29K
Oct 27, 2026$324.70$324.91$323.89$324.04407.85K
Oct 26, 2026$323.88$325.58$323.88$325.22434.16K
Oct 23, 2026$324.96$325.33$323.88$324.39360.03K
Oct 22, 2026$323.50$325.50$323.50$324.96472.55K
Oct 21, 2026$324.46$324.46$321.97$323.56377.75K
Oct 20, 2026$322.99$324.64$322.43$324.34368.83K
Oct 19, 2026$320.30$322.865$320.30$322.41272.64K
Oct 16, 2026$322.80$322.80$320.15$320.86278.7K
Oct 15, 2026$322.13$322.17$320.09$321.20345.44K
Oct 14, 2026$320.41$320.42$319.25$320.12272.34K
Oct 13, 2026$320.93$320.99$318.26$320.01216.89K
Oct 12, 2026$319.91$320.97$318.97$320.96277.22K
Oct 9, 2026$317.06$319.53$317.06$319.40555.3K
Oct 8, 2026$316.61$317.52$316.53$317.52379.36K
Oct 7, 2026$316.62$317.74$316.32$316.35366.19K
Oct 6, 2026$317.10$318.005$316.87$317.05308.41K
Oct 5, 2026$318.23$318.4699$317.10$317.11368.27K
Oct 2, 2026$318.37$318.37$316.78$317.55239.68K

Latest PEN news

The latest Smart Investors Daily articles mentioning PEN.

Stock researchCompany · Overview

PEN research

Overview

Company profile and research snapshot.

Company profile

Domiciled in the US, Penumbra designs, manufactures, and markets an array of thrombectomy and embolization devices and equipment to mechanically remove blood clots. The firm sells mainly to hospitals and physicians. These minimally invasive devices are primarily used in the acute care setting for patients with stroke, pulmonary embolism, deep vein thrombosis, cranial aneurysms, and other vascular diseases.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$311.00
Implied upside
—
Analysts
—
PEN recent ratings
DateFirmRatingTarget
Jul 6, 2026Evercore ISI GroupOutperform—
Jun 11, 2026RBC CapitalSector Perform—
May 7, 2026CitigroupNeutral—
May 7, 2026Evercore ISI GroupOutperform—
Feb 26, 2026Evercore ISI GroupOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 20, 2026

Penumbra's CAVT Technology Receives FDA Clearance for the Treatment of Deep Vein Thrombosis (DVT)

Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced that the U.S. Food and Drug Administration (FDA) has granted clearance for the treatment of deep vein thrombosis (DVT) to the company's Lightning™ computer assisted vacuum thrombectomy (CAVT™) technology. This indication is supported by positive results from the BOLT-DVT Investigational Device Exemption (IDE) trial, which demonstrated the safety and efficacy of CAVT in treating DVT.

Yahoo · Oct 8, 2026

Penumbra (PEN) Clinical Data Puts Its Valuation Back In Focus

Penumbra (PEN) is back in focus after new clinical data from its STORM-PE and STRIKE-PE studies linked real-world wearable activity to recovery outcomes in pulmonary embolism patients treated with its CAVT technology. Recent clinical headlines have landed against a relatively quiet tape for Penumbra, with the share price easing 1.8% over the past month and 0.6% over the past week, even as the year-to-date share price return is positive and the 1-year total shareholder return of 22.2% points...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By